It is understandable that those responsible for paying the bills associated with the increasingly staggering costs of antineoplastic pharmaceutical agents would seek objective measures that could meaningfully help assess their value….
Older Cancer Clinical Trials May Continue to Offer Relevant Lessons Learned
